Micromet is Presenting Four Posters on BiTE(R) Antibodies at the International AACR-NCI-EORTC ...(contains certain forward-looking stateme...)

Date:10/23/2007

contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding the intended utilization of product candidates, the conduct and results of future clinical trials, plans regarding regulatory filings, future research, discovery of new product candidates, and clinical trials, and partnering activities. Factors that may cause actual results to differ materially include the risk that product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later clinical trials, the risks associated with regulatory processes, the risks associated with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborative partners for future revenues under the terms of its existing collaboration agreements, and for further pre-clinical and clinical studies, development and commercialization of product candidates. You are urged to consider statements that include the words "appear," "may," "will," "would," "could," "should," "believes," "estimates," "projects," "potential," "expects," "plans," "anticipates," "intends," "continues," "forecast," "designed," "goal," or the negative of those words or other comparable words to be uncertain and forward-looking. These factors and others are more fully discussed in Micromet's periodic reports and other filings with the SEC, including the "Risk Factors" sections of such reports.

Any forward-looking statements are made pursuant to Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and, as such, speak only as of the date made. Micromet undertakes no obligation to publicly update any forward-looking stateme
'/>"/>

SOURCE Micromet, Inc. Copyright©2007 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related biology technology :

1. Antibodies for Studying NMDA Receptor Protein Expression and Synapse-Specific Immunolabeling
2. Simple, Sensitive Isotyping of Mouse Monoclonal Antibodies
3. Quality control of antibodies using the 2100 bioanalyzer and the Protein 200 Plus assay
4. Mirus announces new method for making antibodies
5. Olympics of biotechnology has international flavor
6. Traffic data firm navigates international business
7. Catalyst International profit exceeds expectations
8. Lack of broadband hamstrings international videoconferencing
9. 30 days to success: Three simple steps to create your own international startup
10. TEKLYNX International announces new RFID software
11. Ruling enforces international trademark electronic filing requirements